{"id":"W2981809579","doi":"10.1093/ofid/ofz359.043","title":"884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Tolerability; Clinical endpoint; Regimen; Adverse effect; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01043388,0.00050375,0.000785056,0.0003387982,0.0004603719,0.0009891131,0.0004469238,0.0007090718,0.003605838],"category_scores_gemma":[0.004500789,0.0002383655,0.001444482,0.0005259329,0.0003020557,0.0006263604,0.0004181548,0.0007278923,0.0004306298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000319147,"about_ca_system_score_gemma":0.0006332914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001784216,"about_ca_topic_score_gemma":0.00390159,"domain_scores_codex":[0.9936793,0.004591561,0.000535869,0.0003787532,0.0005762868,0.0002381731],"domain_scores_gemma":[0.9973448,0.0008865877,0.0007884866,0.0003176399,0.0003368514,0.0003256591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4737112,0.005536554,0.2707072,0.001888164,0.008922485,0.0001351064,0.0007576016,0.0009157771,0.00507684,0.0005275067,0.01170383,0.2201178],"study_design_scores_gemma":[0.0763934,0.1381584,0.7517566,0.0004255779,0.00779798,0.0002996817,0.0003276499,0.00208547,0.002565714,0.0003734133,0.01969918,0.0001169117],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979252,0.007081814,0.0008852732,0.0004067007,0.0001112125,0.001324128,0.004364717,0.00006198983,0.006512138],"genre_scores_gemma":[0.9945478,0.0006322745,0.0007308398,0.0004119978,0.00009218857,0.0006734511,0.001854589,0.000006610123,0.001050144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01043388,"threshold_uncertainty_score":0.05518031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02739097346984783,"score_gpt":0.3417454218479364,"score_spread":0.3143544483780886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}